GURUFOCUS.COM » STOCK LIST » Industrials » Business Services » Proto Script Pharmaceutical Corp (OTCPK:PSCR) » Definitions » Return-on-Tangible-Asset

Proto Script Pharmaceutical (Proto Script Pharmaceutical) Return-on-Tangible-Asset : -566.58% (As of Sep. 2017)


View and export this data going back to 2011. Start your Free Trial

What is Proto Script Pharmaceutical Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Proto Script Pharmaceutical's annualized Net Income for the quarter that ended in Sep. 2017 was $-1.14 Mil. Proto Script Pharmaceutical's average total tangible assets for the quarter that ended in Sep. 2017 was $0.20 Mil. Therefore, Proto Script Pharmaceutical's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2017 was -566.58%.

The historical rank and industry rank for Proto Script Pharmaceutical's Return-on-Tangible-Asset or its related term are showing as below:

PSCR's Return-on-Tangible-Asset is not ranked *
in the Business Services industry.
Industry Median: 4.06
* Ranked among companies with meaningful Return-on-Tangible-Asset only.

Proto Script Pharmaceutical Return-on-Tangible-Asset Historical Data

The historical data trend for Proto Script Pharmaceutical's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Proto Script Pharmaceutical Return-on-Tangible-Asset Chart

Proto Script Pharmaceutical Annual Data
Trend May12 May13 May14 May15 May16
Return-on-Tangible-Asset
-825.00 -125.49 -124.59 -600.00 -507.69

Proto Script Pharmaceutical Quarterly Data
Nov12 Feb13 May13 Aug13 Nov13 Feb14 May14 Aug14 Nov14 Feb15 May15 Aug15 Nov15 Feb16 May16 Sep16 Dec16 Mar17 Jun17 Sep17
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -13,237.36 -1,014.54 -674.43 -566.58

Competitive Comparison of Proto Script Pharmaceutical's Return-on-Tangible-Asset

For the Specialty Business Services subindustry, Proto Script Pharmaceutical's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Proto Script Pharmaceutical's Return-on-Tangible-Asset Distribution in the Business Services Industry

For the Business Services industry and Industrials sector, Proto Script Pharmaceutical's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Proto Script Pharmaceutical's Return-on-Tangible-Asset falls into.



Proto Script Pharmaceutical Return-on-Tangible-Asset Calculation

Proto Script Pharmaceutical's annualized Return-on-Tangible-Asset for the fiscal year that ended in May. 2016 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: May. 2016 )  (A: May. 2015 )(A: May. 2016 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: May. 2016 )  (A: May. 2015 )(A: May. 2016 )
=-0.033/( (0.001+0.012)/ 2 )
=-0.033/0.0065
=-507.69 %

Proto Script Pharmaceutical's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2017 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Sep. 2017 )  (Q: Jun. 2017 )(Q: Sep. 2017 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Sep. 2017 )  (Q: Jun. 2017 )(Q: Sep. 2017 )
=-1.136/( (0.166+0.235)/ 2 )
=-1.136/0.2005
=-566.58 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Sep. 2017) net income data.


Proto Script Pharmaceutical  (OTCPK:PSCR) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Proto Script Pharmaceutical Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Proto Script Pharmaceutical's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Proto Script Pharmaceutical (Proto Script Pharmaceutical) Business Description

Traded in Other Exchanges
N/A
Address
9830 6th Street, Suite 103, Rancho Cucamonga, CA, USA, 91730
Proto Script Pharmaceutical Corp is primarily in the business of repair power wheelchairs and scooters, which are classified as durable medical equipment (DME) products and reimbursable by healthcare insurance providers. It has various contracts with state and governmental insurance providers, among others. These contracts provide the company with the right to sell and repair DME and its health care insurance contracts allow it the ability to service patients nationally. The group currently has its presence of repair facilities in Las Vegas, Nevada, Rancho-Cucamonga, and Anaheim, California.

Proto Script Pharmaceutical (Proto Script Pharmaceutical) Headlines

No Headlines